Brokerages Set Jounce Therapeutics Inc (JNCE) PT at $15.25

Jounce Therapeutics Inc (NASDAQ:JNCE) has received an average recommendation of “Hold” from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $15.25.

Several research analysts recently commented on JNCE shares. Zacks Investment Research cut Jounce Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, March 8th. Robert W. Baird set a $35.00 target price on Jounce Therapeutics and gave the stock a “buy” rating in a research note on Thursday, March 8th. HC Wainwright assumed coverage on Jounce Therapeutics in a research note on Friday, April 27th. They set a “buy” rating and a $33.00 target price for the company. Wells Fargo & Co decreased their price target on Jounce Therapeutics to $10.00 and set a “market perform” rating for the company in a report on Thursday, May 31st. Finally, TheStreet downgraded Jounce Therapeutics from a “c-” rating to a “d+” rating in a report on Tuesday, May 22nd.

Jounce Therapeutics traded down $0.03, hitting $7.76, on Monday, according to MarketBeat Ratings. 4,181 shares of the company were exchanged, compared to its average volume of 586,752. Jounce Therapeutics has a twelve month low of $6.92 and a twelve month high of $29.25. The stock has a market capitalization of $236.15 million, a price-to-earnings ratio of -13.68 and a beta of 5.55.

Jounce Therapeutics (NASDAQ:JNCE) last released its earnings results on Wednesday, May 9th. The company reported ($0.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.09). Jounce Therapeutics had a negative return on equity of 19.90% and a negative net margin of 47.73%. The company had revenue of $11.20 million for the quarter, compared to analyst estimates of $13.33 million. equities research analysts anticipate that Jounce Therapeutics will post -1.54 EPS for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in JNCE. Rhumbline Advisers purchased a new stake in Jounce Therapeutics during the 4th quarter worth about $134,000. MetLife Investment Advisors LLC purchased a new stake in Jounce Therapeutics during the 1st quarter worth about $159,000. Paloma Partners Management Co purchased a new stake in Jounce Therapeutics during the 4th quarter worth about $230,000. Cubist Systematic Strategies LLC purchased a new stake in Jounce Therapeutics during the 1st quarter worth about $243,000. Finally, SG Americas Securities LLC purchased a new stake in Jounce Therapeutics during the 4th quarter worth about $294,000. 91.55% of the stock is owned by institutional investors.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.

Analyst Recommendations for Jounce Therapeutics (NASDAQ:JNCE)

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply